Lidia Daszkiewicz, Gera Goverse, Nataliia Beztsinna, Marjan van de Merbel, Benjamin Visser, Tomas Veenendaal, Emma Spanjaard, Kuan Yuan, Leo Price
Crown Bioscience Netherlands B.V., Leiden, The NetherlandsDespite the increasing number of immunotherapies available in preclinical cancer research and drug discovery pipelines, the number of patients benefiting from these immunotherapies remains extremely low. Moreover, the failure of immunotherapies in clinical trials remains very high to date. These high failure rates could be attributed to the lack of deep understanding of the mechanism of action of drug candidates and to the absence of clinically relevant preclinical models that are suitable for drug screening purposes.
In this poster we address these issues, by detailing our in vitro drug screening platform, which is suitable for high-throughput testing in a physiologically relevant 3D environment. Our preclinical drug testing platform is based on the co-culture of tumor cells with immune cells in 3D. Image analysis is applied to read out effects of drug candidates on immune cell migration, immune cell infiltration and tumoroid killing.
Your privacy is important to us.
We'll never share your information.
© 2025 Crown Bioscience. All Rights Reserved.
Privacy Policy | Imprint | Terms of Service | Privacy Preferences
© 2025 Crown Bioscience. All Rights Reserved. Privacy Policy
2023-02-19
2021-10-27
landing_page
PDX/Databases